Biogen (BIIB) Land & Improvements (2009 - 2010)
Biogen (BIIB) posted quarterly Land & Improvements of $107.6 million for Q4 2010, down 3.24% year-over-year from $111.2 million in Q4 2009, and down 3.24% on a QoQ basis from $111.2 million in Q4 2009.
Biogen (BIIB) Land & Improvements (2009 - 2010) Analysis & Trends
Biogen (BIIB) has reported Land & Improvements for 2 consecutive years, with $107.6 million the latest figure, recorded in Q4 2010.
- In Q4 2010, Land & Improvements fell 3.24% year-over-year to $107.6 million; the TTM figure through Dec 2010 stood at $107.6 million (down 3.24% YoY), while the FY2010 annual figure was $107.6 million, down 3.24% from the prior year.
- Land & Improvements came in at $107.6 million for Q4 2010 at Biogen, down from $111.2 million in the prior quarter.
- The five-year high for Land & Improvements was $111.2 million in Q4 2009, with the low at $107.6 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 107.60 Mn |
| Dec 31, 2009 | 111.20 Mn |